BDNF and glaucoma: We have shown for the first time that in the microbead trabecular occlusion model of glaucoma characterized by an initial severe glaucoma attack [30], a single AAV2-BDNF intraocular injection, when given 3 weeks prior to glaucoma induction, significantly protects RGCs from degeneration.